BCX17725
BCX17725-101
Phase 1 small_molecule active
Quick answer
BCX17725 for Netherton Syndrome is a Phase 1 program (small_molecule) at BIOCRYST PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BIOCRYST PHARMACEUTICALS INC
- Indication
- Netherton Syndrome
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active